Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18706152 | 1.00 | KDM4E (0.46) | KDM4ESMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL19400610 | 0.75 | KDM4E (0.46) | KDM4EPOLBHTTL3MBTL1MAPT | |
| SCHEMBL19295799 | 0.75 | KDM4E (0.46) | KDM4EPOLBHTTL3MBTL1MAPT | |
| SCHEMBL22708745 | 0.75 | KDM4E (0.46) | KDM4EPOLBHTTL3MBTL1MAPT | |
| SCHEMBL21471178 | 0.75 | POLB (0.36) | POLBHTTL3MBTL1 | |
| SCHEMBL3031341 | 0.75 | — | — | |
| SCHEMBL15043322 | 0.75 | — | — | |
| SCHEMBL3031343 | 0.75 | — | — | |
| SCHEMBL16452389 | 0.73 | POLB (0.59) | SMN1; SMN2POLBHTTL3MBTL1 | |
| SCHEMBL14296163 | 0.73 | POLB (0.59) | SMN1; SMN2POLBHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-10273217-B2 | Triazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| WO-2017060202-A1 | TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | MC2R, MC3R, OXTR | KDM4E 2864/4885SMN1; SMN2 3878/4885POLB 2378/4885 |
| US-10273217-B2 | Triazole derivatives | MC2R, MC3R, OXTR | KDM4E 2864/4885SMN1; SMN2 3878/4885POLB 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.